Addyi, or the “female Viagra,” debuted in 2015 to curiosity, criticism and stifling business entanglements. Now the drug, which purportedly treats hypoactive sexual desire disorder, is back. And so is the debate: Is the drug helping a genuine affliction or furthering misconceptions about female arousal, “disease mongering” and shaming some women into believing they’re abnormal? Critics say it’s not for pharmaceutical makers to decide what constitutes a healthy sex drive. And with its halved price and prescriptions by phone, the pink pill is sure to be on the tip of more tongues.